Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00937846 | Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study | PHASE1 | COMPLETED | 4 | — | — | Jul 15, 2009 | Aug 28, 2009 | Jun 27, 2017 | 2 | United Kingdom |
| NCT00743405 | Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects | PHASE1 | COMPLETED | 30 | — | — | May 2, 2008 | Dec 15, 2008 | Jul 21, 2017 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| GSK1034702 | EXPERIMENTAL | Single oral 5 mg dose in liquid formulation |
| Cohort 1 | OTHER | Subjects will be receive GSK1034702 0.5 milligram (mg) following the dose escalation plan |
| Cohort 2 | OTHER | Subjects will be receive GSK1034702 5 mg following the dose escalation plan |
| Name | Type | Description |
|---|---|---|
| GSK1034702 | DRUG | Single oral 5 mg dose in liquid formulation |
| Placebo | DRUG | To match GSK1034702 |
Inclusion Criteria: * Generally healthy. * Male between 35 and 55 years of age. * Willing to use appropriate contraception method. * Weight more than 50 kg. * BMI within the range 19 - 29 kg/m2. * Adequate blood supply to the hand. Exclusion Criteria: * Abuse of drugs or alcohol. * Smoker or hist...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-101 |
| Eli Lilly and Company | LLY | 2 | — | Undisclosed |
| Rhythm Pharmaceuticals, Inc. | RYTM | 1 | — | Undisclosed |